Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Pharmaceutical latest

EMA launches #HealthNotHype campaign
2025-10-24T16:28:00+01:00
Probiotics as nutraceuticals: Bridging science, health and regulation
2025-10-10T11:16:00+01:00
The use of prior knowledge and platform approaches in early vaccine development
2025-10-10T11:15:00+01:00
ICH Q1 guideline revisions to promote innovation and enable global patient access to high-quality medicines
2025-10-10T11:14:00+01:00
Maximising regulatory success through early EMA engagement in drug development
2025-10-10T11:13:00+01:00
Navigating the landscape of paediatric clinical trials under US FDA guidelines
2025-10-10T11:13:00+01:00

Central sourcing of authorised comparators and concomitant medications for multiregional clinical trials in accordance with ICH E17: CMC documentation requirements
2025-10-10T11:12:00+01:00
From trials to approval: Regulatory strategies in early drug development
2025-10-09T16:25:00+01:00
Regulatory Rapporteur October 2025 – Contents
2025-10-09T15:33:00+01:00
NICE increases access to SGLT-2 inhibitors medicines to help treat type 2 diabetes
2025-09-17T12:05:00+01:00
Digital transformation of global regulatory affairs: Then, now and next
2025-09-05T09:10:00+01:00
Target product profile and product profile characteristics for labelling during drug development
2025-09-05T09:10:00+01:00
What could the future of labelling look like? The Gravitate-Health story
2025-09-05T09:09:00+01:00
Electronic patient information: Results of the e-PIL pilot from Belgium and Luxembourg hospitals
2025-09-05T09:09:00+01:00
The EMA/NCA electronic product information initiative: Engagement, implementation and vision for the future
2025-09-05T09:08:00+01:00
September 2025 – Contents
2025-09-05T07:41:00+01:00
Reimagining product information
2025-09-04T14:53:00+01:00
Product information: An overview
2025-09-03T14:40:00+01:00

More pharmaceutical content